Global Induced Pluripotent Stem Cells (iPSCs) Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The opportunities concerning a wide range of diseases including neurodegenerative, metabolic and cardiovascular diseases in a dish for cheaper and faster drug discovery. This may be particularly important in the context of monogenic rare hereditary diseases, where iPSCs can provide an alternative model system to compensate for the lack of a predictive in-vitro human model for drug discovery.
The industry's leading manufacturers are Fujifilm Holding Corporation (CDI), Ncardia and Sumitomo Dainippon Pharma, which accounted for 39.31 percent, 20.24 percent and 13.67 percent of revenue, respectively.

Market Analysis and Insights: Global Induced Pluripotent Stem Cells (iPSCs) Market
The research report studies the Induced Pluripotent Stem Cells (iPSCs) market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Induced Pluripotent Stem Cells (iPSCs) market size is projected to reach US$ 180.7 million by 2026, from US$ 90 million in 2020, at a CAGR of 12.3% during 2021-2026.

Global Induced Pluripotent Stem Cells (iPSCs) Scope and Segment
The global Induced Pluripotent Stem Cells (iPSCs) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Induced Pluripotent Stem Cells (iPSCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.

Segment by Type, the Induced Pluripotent Stem Cells (iPSCs) market is segmented into
Human iPSCs
Mouse iPSCs
Human iPSCs had a market share of 89.65% in 2019, followed by Mouse iPSCs.

Segment by Application, the Induced Pluripotent Stem Cells (iPSCs) market is segmented into
Academic Research
Drug Development and Discovery
Toxicity Screening
Regenerative Medicine
Others
Academic Research is the largest segment of Induced Pluripotent Stem Cells (iPSCs) application,with a share of 32% in 2019.

Global Induced Pluripotent Stem Cells (iPSCs) market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

The major vendors covered:
Fujifilm Holding Corporation (CDI)
Ncardia
Sumitomo Dainippon Pharma
Astellas Pharma Inc
Fate Therapeutics, Inc
Pluricell Biotech
Cell Inspire Biotechnology